Premium
Specialized proresolving mediators in infection and lung injury
Author(s) -
Sandhaus Shayna,
Swick Andrew G.
Publication year - 2020
Publication title -
biofactors
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.204
H-Index - 94
eISSN - 1872-8081
pISSN - 0951-6433
DOI - 10.1002/biof.1691
Subject(s) - inflammation , context (archaeology) , medicine , immunology , disease , coronavirus , lung , ards , covid-19 , infectious disease (medical specialty) , biology , paleontology
Specialized proresolving mediators (SPMs) are endogenous lipid metabolites of long‐chain polyunsaturated fatty acids that are involved in promoting the resolution of inflammation. Many disease conditions characterized by excessive inflammation have impaired or altered SPM biosynthesis, which may lead to chronic, unresolved inflammation. Exogenous administration of SPMs in infectious conditions has been shown to be effective at improving infection clearance and survival in preclinical models. SPMs have also shown tremendous promise in the context of inflammatory lung conditions, such as acute respiratory distress syndrome and chronic obstructive pulmonary disease, mostly in preclinical settings. To date, SPMs have not been studied in the context of the novel Coronavirus, severe acute respiratory syndrome Coronavirus‐2 (SARS‐CoV‐2), however their preclinical efficacy in combatting infections and improving acute respiratory distress suggest they may be a valuable resource in the fight against Coronavirus disease‐19 (COVID‐19). Overall, while the research on SPMs is still evolving, they may offer a novel therapeutic option for inflammatory conditions.